Lv21
130 积分 2026-07-14 加入
Cancer burden and control in China: landscape, trends and challenges
1小时前
已完结
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
1个月前
已完结
Analysis of risk factors for immune checkpoint inhibitor-associated liver injury: a retrospective analysis based on clinical study and real-world data
1个月前
已完结
Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma
1个月前
已完结
Comparison of the efficacy and safety of nebulized beclometasone dipropionate and budesonide in severe persistent childhood asthma
2个月前
已完结
Small Cell Lung Cancer
2个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
2个月前
已完结
Preventing Hand-Foot Syndrome in Patients With Cancer
3个月前
已完结
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
3个月前
已完结
皖公网安备34019202002308
